A novel Klebsiella pneumoniae carbapenemase (KPC) variant, designated bla KPC-5 , was discovered in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate from Puerto Rico. Characterization of the upstream region of bla KPC-5 showed significant differences from the flanking regions of other bla KPC variants. Comparison of amino acid sequences with those of other KPC enzymes revealed that KPC-5 was an intermediate between KPC-2 and KPC-4, differing from KPC-2 by a single amino acid substitution (Pro 103 3Arg), while KPC-4 contained Pro 103 3Arg plus an additional amino acid change (Val 239 3Gly). Transformation studies with an Escherichia coli recipient strain showed differences in the properties of the KPC variants. KPC-4 and KPC-5 both had pIs of 7.65, in contrast with the pI of 6.7 for KPC-2. KPC-2 transformants were less susceptible to the carbapenems than KPC-4 and KPC-5 transformants. These data correlated with higher rates of imipenem hydrolysis for KPC-2 than for KPC-4 and KPC-5. However, KPC-4 and KPC-5 transformants had higher ceftazidime MICs, and the enzymes from these transformants had slightly better hydrolysis of this drug than KPC-2. KPC-4 and KPC-5 were more sensitive than KPC-2 to inhibition by clavulanic acid in both susceptibility testing and hydrolysis assays. Thus, KPC enzymes may be evolving through stepwise mutations to alter their spectra of activity.
Klebsiella pneumoniae carbapenemase (KPC) is a molecular class A serine ␤-lactamase belonging to functional group 2f. KPC was first reported in 2001 after its discovery in a K. pneumoniae clinical isolate collected from North Carolina during the ICARE (Intensive Care Antimicrobial Resistance Epidemiology) surveillance study (35) . An amino acid variant of KPC-1, termed KPC-2, was discovered shortly thereafter in Klebsiella spp. (27, 36) and Salmonella enterica (16) . However, a recent correction of the bla KPC-1 sequence has indicated that the bla KPC-1 and bla KPC-2 sequences are identical, and thus, KPC-1 and KPC-2 are the same enzyme (35) . Mutations in the bla KPC-2 structural gene have resulted in two variants, bla (33) and bla (20) .
bla KPC has been detected in several members of the Enterobacteriaceae, not only on the East Coast of the United States (23) but also in several other U.S. locations (5, 13, 15, 24, 26) . Most notably, Klebsiella spp. harboring the bla KPC gene have become endemic to New York City (3), and as a result, the New York Health Department has issued an advisory to control the spread of these organisms (8) . KPC has since become a global concern, with the identification of this ␤-lactamase gene in organisms from various locations worldwide (18) (19) (20) (28) (29) (30) . In Colombia alone, Villegas et al. (29) have reported the presence of bla KPC-2 in K. pneumoniae and Citrobacter freundii and the first detection of bla KPC in Pseudomonas aeruginosa (28) . The acquisition of bla KPC by different bacterial species may be attributed to its location on transferable plasmids or to dissemination by mobile genetic elements. A study by Naas et al. (17) has described the association of bla with transposon Tn4401 on plasmids of various sizes from different organisms. Similarly, bla has been shown to reside on plasmids that can be moved through conjugal transfer (10, 33) .
KPC-2 and KPC-3 hydrolyze several different classes of ␤-lactams, including the carbapenems (1, 36) . Both enzymes were highly efficient at hydrolyzing nitrocefin, cephalothin (cefalotin), and cephaloridine, modestly efficient against the carbapenems and cefotaxime, and inefficient against cefoxitin and ceftazidime. In comparison, KPC-3 had slightly better hydrolytic activity against ceftazidime than KPC-2 (1). Despite the ability to hydrolyze the carbapenems in in vitro assays, KPC-producing organisms do not always display a resistant phenotype; KPC-2-and KPC-3-positive Klebsiella and Enterobacter spp. often have carbapenem MICs below the susceptible breakpoint (3, 4) . KPC-positive strains are typically resistant to the penicillins, extended-spectrum cephalosporins, and aztreonam, but MICs of these drugs and the carbapenems are reduced in the presence of clavulanic acid due to enzyme inhibition (33, 36) .
In a recent surveillance study of the mechanisms associated with carbapenem resistance in P. aeruginosa strains from Puerto Rico (32) , bla KPC was detected in two genetically unrelated strains with high imipenem MICs (Ͼ64 g/ml). The first P. aeruginosa strain, PR100, possessed bla KPC-2 , while a novel KPC variant, bla , was discovered in the second strain, PR280. The current study describes the characterization of bla and the properties of the encoded enzyme, KPC-5, in comparison with other bla KPC variants. C-3Ј), which flank the bla KPC structural gene but do not include promoter sequences. The 969-bp amplicons were cloned into the pCR2.1 vector and then subcloned into vector pACYC184 (Fermentas Inc., Glen Burnie, MD) using the restriction enzyme EcoRI (Invitrogen). The EcoRI site of pACYC184 is located within the chloramphenicol resistance gene, cat, and transcription of the cloned bla KPC genes initiates from the cat promoter. This method ensured that expression of the bla KPC genes would be equal between transformants, enabling direct comparisons between the cloned genes. The plasmids containing the bla KPC genes were transformed into competent E. coli TOP10 cells (Invitrogen).
IEF and ␤-lactamase hydrolysis assays. Crude ␤-lactamase extracts were prepared from the bla KPC transformants, and the isoelectric points of the KPC variants were determined by analytical isoelectric focusing (IEF) on an Ampholine polyacrylamide gel (pH range, 3 to 10) according to previously described methods (27) . Extracts from the bla KPC transformants were also used to assess the hydrolytic properties of the KPC variants by a spectrophotometric hydrolysis assay (27) using 100 M concentrations of cephalothin, cefotaxime, and imipenem and a 50 M concentration of ceftazidime as substrates. For inhibition assays, clavulanic acid (final concentration, 100 M) was incubated with crude extracts from the bla KPC transformants at 30°C for 5 min in phosphate buffer (pH 7.0) prior to the addition of the substrate.
Nucleotide sequence accession number. The bla KPC-5 nucleotide sequence was deposited in the GenBank database with accession number EU400222.
RESULTS
Sequence comparisons of the variant KPCs. During the preparation of this article, the sequence of another novel bla KPC allele, bla , was published in GenBank (accession number EU555534) and was included in the sequence analysis for all published bla KPC s below. DNA sequence analysis of the structural gene showed that bla was 99% identical to both bla KPC-2 and bla , with only single-nucleotide differences from either ␤-lactamase gene. bla had the same nucleotide substitution at position 308 (C3G) as bla KPC-4 compared with bla KPC-2 , bla KPC-3 , and bla , resulting in an amino acid change from proline to arginine (Table 1) . While bla and bla contained a guanosine at position 716, coding for a glycine amino acid, the bla KPC-2 , bla KPC-3 , and bla KPC-5 sequences differed at this nucleotide location, with a thymine residue, coding for a valine (Table 1) . bla was the only gene to have a thymine substitution at position 814 (coding for tyrosine 272 ), whereas the other bla KPC s possessed a cytosine (coding for histidine 272 ).
To evaluate the genetic and evolutionary relationships of the bla KPC variants, a minimum spanning tree was constructed on the basis pf sequence divergence. The spanning tree ( Fig. 1) identified bla KPC-2 as the founding (i.e., ancestral) sequence, while bla KPC-3 , bla , and bla KPC-6 formed three separate branches as a result of single-nucleotide polymorphisms (SNPs). bla and bla KPC-6 serve as intermediate steps to the selection of bla KPC-4 (two SNPs), which may emerge through either pathway ( Fig. 1) . bla and bla have the highest number of nucleotide changes between variants, with three SNPs. 
a Nucleotide (amino acid) positions in bla KPC s.
WOLTER ET AL. ANTIMICROB. AGENTS CHEMOTHER.
Upstream sequence and transcriptional start site of bla KPC-5 . Alignment of the upstream regions from several bla KPC-2 (GenBank accession numbers EU176014, EU176013, EU176012, EU176011, DQ989639, DQ523564, and AF481906) and bla (GenBank accession number AM774409) sequences published in GenBank demonstrated a high degree of sequence identity (data not shown). The sequence flanking the 5Ј end of bla has yet to be reported. In order to determine if bla and bla KPC-5 share the same upstream region as the bla KPC genes mentioned above, PCR was performed using flanking primers designed from bla KPC-2 . A PCR product was generated for bla , and sequence analysis showed that the first 363 bases directly upstream of the translational start codon of bla were identical to the sequence upstream of bla KPC-2 (data not shown). No PCR product could be amplified for bla by using multiple flanking primer sets, suggesting divergence in the flanking sequences. Using a genome-walking technique, 2,159 bases were sequenced upstream of the bla KPC-5 translational start codon (Fig. 2) . Although the first 20 bases directly upstream of the bla KPC-5 structural gene were identical to the corresponding region in bla KPC-2 , the next 65 bases showed no similarity with the bla KPC-2 flanking sequence or with any sequence in GenBank (Fig. 2) . Adjacent to this sequence was a 1,628-bp DNA fragment with 100% identity to a portion of the transposable element Tn5563 in Pseudomonas alcaligenes plasmid pRA2 (GenBank accession number PAU88088). This region contained the 39-bp terminal repeat, resolvase gene (tnpR), and stem-loop found in Tn5563. Although a transposase, tnpA, is also present within Tn5563, the sequence upstream of the 1,628 bp fragment was divergent from this gene. Instead, the remaining 392 bp showed 100% identity to the tnpA2 transposase gene from IS6100, present in Sphingomonas paucimobilis (GenBank accession number AY331258).
Since the upstream region differed significantly from those of the other bla KPC alleles, 5Ј RACE was used to map the transcriptional start site of bla in order to aid in promoter identification. Sequencing of a 424-bp bla KPC-5 cDNA product identified the start site of transcription at a cytosine residue 70 bases upstream of the translational start codon (Fig. 2) and within the 65-bp sequence that showed no homology to any known sequence. A putative Ϫ10 promoter element (TAGGAT) was also predicted within this 65-bp region; however, the putative Ϫ35 promoter element (TTGCTC) was identified within the 39-bp terminal repeat region (Fig. 2) .
The isoelectric points of KPC-4 and KPC-5 differ from that of KPC-2. IEF of crude extracts from P. aeruginosa strains PR100 and PR280 showed the presence of multiple ␤-lactamases with pIs of 6.7 (PR100), 7.65 (PR280), and 8.0 (both strains). KPC-2 and KPC-4 have previously been shown to have pIs of 6.7 and 7.65, respectively (25, 36) . To determine if the band at the pI of 7.65 in PR280 represented KPC-5, from strains PR100 and E624, respectively, were also cloned into pACYC184, and crude extracts from KPC-2 and KPC-4 transformants were also included. TOP10 transformants harboring bla KPC-4 and bla KPC-5 produced a ␤-lactamase with a pI of 7.65, whereas a ␤-lactamase with a pI of 6.7 was present in the bla KPC-2 transformant (data not shown). All three KPCs showed partial inhibition by clavulanic acid (data not shown). Bands other than the one representing KPC enzymes were not visible upon IEF analysis using the extracts obtained from the E. coli transformants. Antimicrobial susceptibilities of transformants with KPC-2, KPC-4, and KPC-5. The susceptibilities of the E. coli TOP10 transformants containing bla KPC-2 , bla KPC-4 , and bla KPC-5 to several ␤-lactams were examined, and results are presented in Table 2 . Of note, the structural genes of the bla KPC variants were cloned into a low-copy-number vector, and KPC expression was driven by the chloramphenicol promoter of the vector. This eliminated differences in expression levels, allowing for systematic comparison between variants. The MICs of all drugs tested, except cefoxitin, were at least 16-fold higher for the transformants than for the host strain. Only a modest decrease in susceptibility to cefoxitin was observed, with two-to eightfold increases in the MICs for the transformants. In comparison to each other, KPC transformants had similar MICs of cefotaxime, cefepime, and aztreonam but differed in their susceptibilities to the remaining drugs. MICs of cefoxitin and all three carbapenems were at least four-to eightfold higher for the KPC-2 transformant than for the KPC-4 transformant, while MICs for the KPC-5 transformant were two-to fourfold lower than those for the KPC-2 transformant. The KPC-2 transformant was also fourfold less susceptible to piperacillintazobactam than the KPC-4 transformant. The KPC-4 transformant, however, was less susceptible to ceftazidime than the KPC-2 transformant, with MICs differing at least eightfold. As before, the MIC of ceftazidime for the KPC-5 transformant (128 g/ml) fell between the MICs for the KPC-2 (32 g/ml) and KPC-4 (Ͼ128 g/ml) transformants. While MICs for the KPC-2 transformant were interpreted as intermediate to meropenem and resistant to imipenem, ertapenem, and cefoxitin, MICs of each carbapenem and cefoxitin for the KPC-4 transformant were in the susceptible range. The KPC-5 transformant was resistant to ertapenem and intermediate to cefoxitin but susceptible to imipenem and meropenem.
The addition of clavulanic acid (4 g/ml) reduced the imipenem MIC for the KPC-2 transformant fourfold (Table 2) . Interestingly, MICs of imipenem decreased at least 32-fold for the KPC-4 and KPC-5 transformants in the presence of clavulanic acid, suggesting that KPC-4 and KPC-5 were more sensitive to inhibition by clavulanic acid.
Comparison of hydrolytic activities. The differences in the susceptibilities of the transformants, described above, suggested that the KPC variants may have different hydrolytic efficiencies. To test this, the hydrolysis rates for several substrates were examined by using a spectrophotometric assay and extracts from the E. coli transformants containing KPC-2, KPC-4, or KPC-5. KPC-2 hydrolyzed cephalothin at levels approximately 7.5-and 3.5-fold higher than KPC-4 and KPC-5, respectively (Table 3 ). In addition, KPC-2 was more active against imipenem, with hydrolysis rates approximately 6-and 3.5-fold higher than those of KPC-4 and KPC-5, respectively. KPC-4 and KPC-5 were more efficient at hydrolyzing ceftazidime than KPC-2. KPC-5 showed slightly more activity against cephalothin (ϳ2-fold) and imipenem (ϳ1.7-fold) than KPC-4. KPC-2, KPC-4, and KPC-5 hydrolyzed cefotaxime with similar efficiencies (Table 3) .
As in the susceptibility data, clavulanic acid was more inhibitory against KPC-4 and KPC-5 than against KPC-2 in the hydrolysis assays (Table 3 ). The rates of cephalothin and cefotaxime hydrolysis by KPC-2 decreased approximately 2.6-fold in the presence of clavulanic acid (100 M). However, more-substantial reductions in hydrolytic activity were ob- served for KPC-4 against cephalothin (ϳ8.6-fold decrease) and cefotaxime (ϳ8.8-fold decrease) with the addition of clavulanic acid. Similarly, rates of cephalothin and cefotaxime hydrolysis by KPC-5 declined 7.7-fold and 7.1-fold, respectively, in the presence of clavulanic acid.
DISCUSSION
Since the discoveries of the synonymous KPC-1 and -2 enzymes, the KPC family has grown to include four additional variants, KPC-3 through KPC-6. While bla KPC-2 and bla have been detected in several members of the Enterobacteriaceae and P. aeruginosa (bla KPC-2 only), bla has been found in only two bacterial species, Enterobacter cancerogenus (20) and K. pneumoniae (25) . bla and bla KPC-6 represent newly discovered variants in P. aeruginosa and K. pneumoniae, respectively. Using the aligned sequences of the bla KPC s, a minimum spanning tree indicated that bla KPC-2 was the founding (i.e., ancestral) sequence from which variants have arisen through nucleotide substitutions in this gene. The fact that bla KPC-2 -positive organisms were described in numerous reports prior to the discovery of the first variant, bla (23), also supports the hypothesis that bla KPC-2 is the prototype sequence. KPC-3, KPC-5, and KPC-6 each differ from KPC-2 by a single amino acid change. KPC-5 and KPC-6 also differ from KPC-4 by a single amino acid variation. As shown by the spanning tree, KPC-4, a two-amino-acid variant of KPC-2, may have emerged through a sequential process where KPC-5 and/or KPC-6 represents an intermediate step.
The mutations in the variant KPCs affect the characteristics of the enzymes. The shift in the pI from 6.7 (KPC-2 and KPC-3) to 7.65 (KPC-4 and KPC-5) can be explained by the amino acid substitution of arginine (basic, positively charged) for proline (polar, uncharged) at position 103. An increase in pI has also been observed between the ␤-lactamases TEM-35 (pI 5.2) and TEM-39 (pI 5.4) and between CTX-M-39 (pI 7.0) and CTX-M-26 (pI 8.0), where the enzymes differ by a single arginine substitution (6, 11) . However, the substitution of glycine for valine at position 239 in KPC-4 and KPC-6 should not influence the pI of either enzyme, since both amino acids are nonpolar and uncharged. Indeed, KPC-4 and KPC-5 shared the same pI despite the Gly 239 change in KPC-4.
The amino acid changes between KPCs also appear to influence the kinetic properties of the enzymes. In comparison to KPC-2, KPC-3 was shown to have a higher rate of hydrolysis for ceftazidime but a lower affinity for cefoxitin (1) . Similarly, KPC-4 and KPC-5 have spectra of activity for certain ␤-lactams different from that of KPC-2. In this study, the bla KPC-2 transformant was less susceptible than other bla KPC transformants to the carbapenems, which can be attributed to more efficient hydrolysis of this drug class. Conversely, extracts from bla and bla KPC-5 transformants had slightly better rates of ceftazidime hydrolysis (twofold), which may explain why their MICs were higher than that for the bla KPC-2 transformant, although increased affinity for ceftazidime may also play a role, as in KPC-3 (1). Interestingly, the susceptibility and hydrolysis results for KPC-5 always fell between the ranges of KPC-2 and KPC-4, with most similarity to the KPC-4 results. These data suggest an evolutionary transformation of KPCs from an efficient carbapenemase (KPC-2) to variants with better ceftazidimase activity (KPC-4) through stepwise mutation. This situation is reminiscent of the extended-spectrum ␤-lactamases TEM and SHV, which have modified activities to include ceftazidime as a result of mutation (2) . A reduction in KPC activity, however, appears to be the cost for this conversion. While the susceptibility and hydrolysis assays suggest variability in the enzymatic properties of the KPC enzymes, we cannot rule out the possibility that the kinetic differences result from altered protein levels due to the mutation(s) within KPC-5 and KPC-4. Other studies have demonstrated that specific mutations in ␤-lactamases affect protein stability (12, 22) or translation efficiency (12) , ultimately reducing the amount of enzyme. Since ␤-lactamase levels were not measured in the crude lysates from our study, the results of the hydrolysis assays should be confirmed using purified enzymes.
While the Pro 103 3Arg mutation may confer more activity against ceftazidime, this change renders the enzyme more sensitive to inhibition by clavulanic acid. Susceptibility to imipenem increased at least 32-fold in the bla and bla transformants with the addition of clavulanic acid, but only a 4-fold increase was observed for transformants expressing bla KPC-2 . These changes in susceptibility were due to the different sensitivities of the enzymes to clavulanic acid inhibition, as demonstrated by substrate hydrolysis. The most dramatic decrease in the hydrolysis rates occurred for KPC-4 in the presence of clavulanic acid (100 M), followed by KPC-5. Among the three enzymes tested, KPC-2 was the least affected by clavulanic acid. KPC-4 and KPC-5 are unique among ␤-lactamase variants in that they became more sensitive to inhibition instead of exhibiting a more dramatic switch from inhibitor sensitivity to inhibitor resistance (2) or a transition from inhibitor resistance to inhibitor sensitivity (9) .
The flanking regions of the bla KPC genes sequenced thus far, excluding bla KPC-5 , were related to Tn4401 (17) . Conversely, bla KPC-5 had a unique upstream region, with components from both Tn5563 and IS6100A present. Tn5563 is a class II transposon flanked on either side by 39-bp terminal inverted repeats, encodes a resolvase and a transposase, and carries three open reading frames with similarities to genes encoding mercuric ion transport proteins MerP and MerT and the regulatory protein MerR (34) . While the first terminal inverted repeat and the complete resolvase gene, tnpR, were directly upstream of bla , the remaining sequence was identical to that of the transposase gene, tnpA2, of IS6100A. IS6100A may have inserted into the backbone of Tn5563 in a manner similar to the insertion of the class I integron In32 into Tn5563 (21) .
bla transcription initiates at a cytosine residue located near the 39-bp terminal repeat of Tn5563. A putative Ϫ10 promoter element was identified just downstream of the terminal repeat, but the putative Ϫ35 promoter element was located within the terminal repeat. Outwardly directed Ϫ35 promoter elements have been discovered within the terminal inverted repeats of several insertion sequences (14) , causing the overexpression of neighboring genes when resident Ϫ10 promoter elements are proportionally spaced.
As demonstrated in this study, the KPC variants have different susceptibilities and hydrolytic properties. This may contribute to the difficulty that clinical laboratories have encountered in identifying KPC-producing organisms. Detecting the presence of these enzymes in clinical isolates is imperative, regardless of their susceptibility patterns, because of the potential for the spread and evolution of these enzymes in response to local selective pressures.
